How should I treat a cold sore (herpes labialis) in an otherwise healthy adult?

Cold Sore Treatment

For an otherwise healthy adult with herpes labialis, initiate oral valacyclovir 2g twice daily for 1 day at the first sign of symptoms (prodrome or erythema stage), or alternatively use famciclovir 1500mg as a single dose or 750mg twice daily for 1 day. 1

Treatment Algorithm

First-Line: Short-Course Oral Antivirals

The FDA-approved short-course oral regimens are superior to topical treatments and should be your default choice 1, 2:

Preferred Options:

• Valacyclovir: 2g twice daily for 1 day (most convenient) 1
• Famciclovir: 1500mg single dose OR 750mg twice daily for 1 day 1
• Acyclovir: 400mg 5 times daily for 5 days (less convenient, requires more frequent dosing) 1

Critical Timing: Treatment must be initiated within the first hour of symptom onset, ideally during the prodromal stage or at erythema, and no later than 48 hours from lesion onset 1, 2. This narrow therapeutic window is essential for efficacy.

Evidence Supporting Oral Therapy

Oral antivirals demonstrate clear benefits across all disease measures 1:

• Valacyclovir reduces median episode duration from 5.0 days (placebo) to 4.0-4.5 days (p<0.001)
• Famciclovir reduces median healing time from 6 days to 4 days (p=0.010)
• Pain resolution occurs faster with all oral agents

The most recent network meta-analysis 3 from 2023 found that combination therapy of oral valacyclovir plus topical clobetasol 0.05% was most effective, reducing healing time by 3.50 days compared to placebo. However, this combination approach is not standard practice and requires corticosteroid consideration.

Second-Line: Topical Antivirals

Use only if oral therapy is contraindicated or unavailable 2:

• Penciclovir 1% cream: Apply every 2 hours while awake for 4 days (reduces healing time by 0.7 days) 4
• Acyclovir 5% cream: Apply 5 times daily for 4 days (reduces episode duration by 0.5 days) 5

Important Caveat: Topical antivirals are significantly less effective than oral agents and do NOT prevent lesion progression to classical vesicular stages 5, 2.

Avoid: Acyclovir + Hydrocortisone Combination

Despite being marketed, the acyclovir-hydrocortisone combination shows no significant advantage over acyclovir alone in preventing ulceration or reducing episode duration 6. The added corticosteroid introduces unnecessary risks including potential infection aggravation and hypersensitivity reactions without proven benefit.

Special Considerations

Chronic Suppressive Therapy

For patients with ≥6 episodes per year or severe recurrences 1, 2:

• Acyclovir: 400mg twice daily continuously
• Valacyclovir: 500mg once daily for 16 weeks
• Famciclovir: Similar suppressive dosing

Suppressive therapy significantly reduces recurrence frequency: acyclovir showed 53% fewer clinical recurrences versus placebo (p=0.009), and valacyclovir resulted in 60% of patients remaining recurrence-free versus 38% with placebo 1.

Safety Profile

All three oral antivirals are well-tolerated with minimal adverse events 1:

• Headache is most common (mild)
• Nausea and diarrhea occur in <10% of patients
• No serious adverse events reported in clinical trials
• Safe for adolescents and adults

Common Pitfalls to Avoid

1. Delayed initiation: Waiting beyond the prodromal/early erythema stage significantly reduces efficacy
2. Choosing topical over oral: Oral agents have superior bioavailability and efficacy
3. Using acyclovir-hydrocortisone: No added benefit with potential corticosteroid risks
4. Inadequate dosing frequency: Acyclovir requires 5 times daily dosing; valacyclovir/famciclovir offer better compliance with once or twice daily regimens

Patient Counseling

Emphasize that patients should keep medication on hand and self-initiate treatment immediately at first symptoms. The brief therapeutic window means delayed treatment substantially reduces effectiveness 1, 2.